272
Participants
Start Date
December 21, 2017
Primary Completion Date
July 1, 2025
Study Completion Date
July 1, 2025
Autogene cevumeran
Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
Atezolizumab
Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
CHU de Liège (Sart Tilman), Liège
UZ Gent, Ghent
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Clinica Universitaria de Navarra, Pamplona
Fachklinik für Lungenerkrankungen, Immenhausen
Sarah Cannon Res Inst, Nashville
University of Oklahoma Health Sciences Center, Oklahoma City
Akademiska sjukhuset, Onkologkliniken, Uppsala
HonorHealth Research Institute ? Bisgrove, Scottsdale
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas
UCSF Comprehensive Cancer Ctr, San Francisco
Stanford Cancer Center, Stanford
Providence Oncology and Hematology Care Eastside, Portland
Seattle Cancer Care Alliance, Seattle
University of Colorado, Aurora
Yale University Cancer Center, Smilow Cancer Hospital, New Haven
Massachusetts General Hospital., Boston
Dana Farber Can Ins, Boston
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Center, Toronto
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
Universitair Medisch Centrum Utrecht, Utrecht
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
Barts & London School of Med, London
Southampton General Hospital, Southampton
Lead Sponsor
Collaborators (1)
BioNTech SE
INDUSTRY
Genentech, Inc.
INDUSTRY